Sanofi
Why Robinhood?
You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.
SNY Key Statistics
SNY News
Shares of NVIDIA Corp. ( NVDA ) fell 0.3% following news that the company is planning to acquire assets from Groq, a designer of high-performance AI accelerator...
In recent months, Novavax has been shifting from direct commercial vaccine sales toward a royalty- and milestone-focused partnership model with Sanofi, while co...
A healthcare titan wants to buy the biotech's vaccines. Shares of Dynavax Technologies (DVAX +38.19%) popped on Wednesday after the vaccine maker struck a deal...
More SNY News
William Blair downgraded Dynavax (DVAX) to Market Perform from Outperform after Sanofi (SNY) announced it will acquire the company for $15.50 per share. The ana...
Stock index futures are little changed ahead of the holiday shortened session after the benchmark S&P 500 set a record on Tuesday. U.S. stock markets are due to...
Here are some of the stocks making notable moves in Wednesday's premarket action: Dynavax Technologies stock is up 37% after the vaccine maker agreed to be acq...
Sanofi (SNY) announced on Wednesday that the U.S. FDA issued a complete response letter regarding its marketing application for tolebrutinib, rejecting the drug...
06:34 EST Dynavax (DVAX) jumps 37% to $15.31 after buyout offer from Sanofi (SNY) Published first on TheFly – the ultimate source for real-time, market-moving...
Sanofi SA (NASDAQ:SNY) on Wednesday agreed to acquire Dynavax Technologies Corporation (NASDAQ:DVAX) for $15.50 per share in cash, reflecting a total equity val...
Sanofi (SNY) said it will buy Dynavax Technologies (DVAX) for about $2.2 billion in cash to grow its vaccines business. The French drugmaker will pay $15.50 per...